LENZ Therapeutics (LENZ) Corporate presentation summary

Market opportunity and unmet need

• Presbyopia affects 128 million people in the US, representing a $3 billion market opportunity with strong patient interest in non-glasses solutions.

• Over 60% of presbyopes would consider an eye drop solution, with clear early adopter segments including contact lens wearers, post-LASIK patients, and active lifestyle consumers.

• Blockbuster potential is projected at $3B with conservative 6% adoption and 42% refill rate, and 75% of study participants would continue using the product.

Product profile and differentiation

• VIZZ (aceclidine ophthalmic solution 1.44%) is the only FDA-approved, pupil-selective miotic eye drop for presbyopia, launched in October 2025.

• Aceclidine is uniquely selective for the iris sphincter muscle, minimizing ciliary muscle stimulation and optimizing near vision restoration.

• 99% of patients achieved the ideal pupil size for near vision, and VIZZ is the only aceclidine-based drop with this selectivity.

Clinical efficacy and safety

• VIZZ provides rapid and sustained improvement: 91% of patients improved near vision by 2 lines within 30 minutes, and 69% maintained this at 10 hours.

• About 70% of patients achieved 20/40 functional near vision for up to 10 hours after a single dose.

• No serious treatment-related adverse events were reported; most side effects were mild, transient, and self-resolving, with less than 4% discontinuation.